Rheumatic Heart Disease - How are We in 2019, Have We Evolved?

Volume 32, Nº 5, September and October 2019

DOI: http://www.dx.doi.org/10.5935/2359-4802.20190041

EDITORIAL

Rheumatic Heart Disease - How are We in 2019, Have We Evolved?

+ Author

Andressa Mussi Soares

Acute rheumatic fever (ARF) is the result of na autoimmune response to pharyngitis caused by infection with the sole member of the group A Streptococcus (GAS), Streptococcus pyogenes. ARF leads to a condition characterized by various combinations of joint pain and swelling, cardiac-valve regurgitation with the potential for secondary heart failure, chorea, skin and subcutaneous manifestations, and fever.

Rheumatic heart disease (RHD) is a disease of poverty that affects children and working-age adults. The global economic impact of early death from RHD is still very high. In Brazil, the average cost of RHD-related damage is around 89 million Brazilian reals (close to US$ 28 million) a year. Information from the Brazilian Unified National Health System database (DATASUS) indicates a cardiac mortality rate of about 7.9% from chronic rheumatic fever (RF).¹

Keywords: Rheumatic heart disease; chronic valvular heart disease; control programs; corticosteroids; echocardiography.

Videos

Moderator: Dr. Claudio Tinoco Mesquita, IJCS chief editor and Postgraduate Coordinator in Cardiovascular Sciences at Universidade Federal Fluminense

Interview with the President of SBC, Dr. Marcelo Queiroga, about the Effects of COVID-19 on the heart and actions of SBC in combating the pandemic.

Dr. Francisco José Gondim Pitanga

Should Physical Activity Be Considered Essential During the COVID-19 Pandemic?

Dr. Christiane Wiefels

The Role of 18F-FDG PET/CT in Cardiac Sarcoidosis

Dr. Enrique Terán

Treatment Eligibility and Therapeutic Responses of an Ecuadorian Population at High Cardiovascular Risk Based on the ATP III Guidelines

Tips for a Successful Publication

How to write and submit a paper